This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohle-Boetani, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohle-Boetani, J. C.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 103 No. 4 April 1999, pp. 703-710

Preventing Neonatal Group B Streptococcal Disease: Cost-Effectiveness in a Health Maintenance Organization and the Impact of Delayed Hospital Discharge for Newborns Who Received Intrapartum Antibiotics

Received Aug 10, 1998; accepted Oct 28, 1998.

Janet C. Mohle-Boetani*, Tracy A. LieuDagger , G. Thomas RayDagger , Gabriel EscobarDagger , and for the Neonatal GBS Prevention Working Group*

From the * California Department of Health Services, Berkeley; and the Dagger  Division of Research, the Permanente Medical Group, Oakland, California.

Objectives.  To estimate the cost and health benefits of implementing a risk factor-based prevention strategy for early-onset neonatal group B streptococcal (GBS) disease, using baseline assumptions and costs from a health maintenance organization. With the risk factor-based strategy, intrapartum antibiotics (IPAs) would be provided to women with fever, prolonged rupture of membranes, or preterm labor. A second objective was to determine the impact of an increased length of stay for well term infants with mothers who received IPAs.

Methods.  We used decision analysis to compare the costs and benefits of the prevention strategy with usual obstetric practice for a cohort of 100 000 women and their newborn infants. We derived baseline values from a previous study based on chart review and automated cost data from a health maintenance organization in Northern California. In sensitivity analyses, we varied baseline assumptions, including additional costs for observing well term infants who received IPAs.

Results.  If adherence to guidelines were 100%, 17% of mothers would receive IPAs at a cost of $490 000; $1.6 million would be saved by preventing 66 GBS cases (64% reduction). The net savings would be $1.1 million and 61 life-years. The net cost is sensitive to the cost of caring for well infants who received IPAs. If each term infant of a mother who received IPAs had 1 more day of observation than other term infants, there would be a net cost of $8.1 million; the cost per GBS case prevented would be $120 000 and the cost per life-year saved would be $130 000.

Conclusions.  Implementation in a health maintenance organization of a risk factor-based strategy to prevent neonatal GBS disease can prevent substantial disease and be cost saving. However, if the length of hospital stay were extended among well term infants whose mothers received IPAs, the strategy would be relatively costly compared with other medical interventions.  Key words:  neonatal, sepsis, meningitis, streptococcal, cost-effectiveness, health maintenance organization, prevention, antibiotics, hospital stay.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
R. S. Gibbs, S. Schrag, and A. Schuchat
Perinatal Infections Due to Group B Streptococci
Obstet. Gynecol., November 1, 2004; 104(5): 1062 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. B. Hyde, T. M. Hilger, A. Reingold, M. M. Farley, K. L. O'Brien, and A. Schuchat
Trends in Incidence and Antimicrobial Resistance of Early-Onset Sepsis: Population-Based Surveillance in San Francisco and Atlanta
Pediatrics, October 1, 2002; 110(4): 690 - 695.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. A. Haberland, W. E. Benitz, G. D. Sanders, J. B. Pietzsch, S. Yamada, L. Nguyen, and A. M. Garber
Perinatal Screening for Group B Streptococci: Cost-Benefit Analysis of Rapid Polymerase Chain Reaction
Pediatrics, September 1, 2002; 110(3): 471 - 480.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. J. Escobar, D.-k. Li, M. A. Armstrong, M. N. Gardner, B. F. Folck, J. E. Verdi, B. Xiong, R. Bergen, and for the Neonatal Infection Study Group
Neonatal Sepsis Workups in Infants >= 2000 Grams at Birth: A Population-Based Study
Pediatrics, August 1, 2000; 106(2): 256 - 263.
[Abstract] [Full Text]

Home page
 NEJMHome page
S. J. Schrag, S. Zywicki, M. M. Farley, A. L. Reingold, L. H. Harrison, L. B. Lefkowitz, J. L. Hadler, R. Danila, P. R. Cieslak, and A. Schuchat
Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis
N. Engl. J. Med., January 6, 2000; 342(1): 15 - 20.
[Abstract] [Full Text] [PDF]